RDRobin Dharia

Robin Dharia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Robin Dharia has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Reimagining Cryptogenic Stroke Care: Collaborative Care and Inpatient Insertable Cardiac Monitors for Detection of Atrial Fibrillation

    by Nabeel A. Herial, Daniel Robert Frisch, Elan Miller, Priyadarshee Patel, Alfredo Munoz, Melissa Warren, Jane Khalife, Shyam Majmundar, Nathan Farkas, Shaista Alam, et al.

    Background: Atrial fibrillation (AF) is a known risk factor of ischemic stroke and AF-related stroke is twice more likely to be fatal. Long-term cardiac rhythm monitoring using insertable cardiac monitors (ICMs) has greater diagnostic yield compared to conventional monitoring in detecting AF, and clinical utility of ICMs is established in cryptogenic stroke, strokes due to large artery atherosclerosis and small vessel disease. A registry-based study was conducted to evaluate inpatient implantation of ICMs and feasibility of vascular and interventional neurologists as implanters using novel collaborative clinical care pathway for cryptogenic stroke. Methods: Multiyear data from a hospital-based registry at a comprehensive stroke center was reviewed to evaluate inpatient ICM implantation and test feasibility of vascular and interventional neurologists/VIN as implanters of ICMs together with cardiology using a novel collaborative care pathway. Reviewed data included number of ICMs, implantation trend, inpatient vs. outpatient setting, time to ICM implantation, inpatient workflow including defined roles of team members, and AF detection rate. Results: Total of 290 ICMs for cryptogenic stroke were implanted when patients where in the hospital and 78 as outpatient after discharge during the study period of 3 years. The majority of inpatient ICM implants were performed by VIN (n=181) and ICM use for cryptogenic stroke increased by 130%. Average time to inpatient ICM implant was 4.1 days with 77% in 5 and 95.5% within 10 days post-stroke. Average time to out-patient ICM placement was 57 days. AF detection rate of 36.5% was noted at 24 months with a collaborative care pathway. Discussion: Inpatient implantation of ICMs is feasible and was performed safely and efficiently by VIN together with cardiology using a collaborative care pathway. Increase in utilization of ICMs and higher AF detection rates were noted. Findings support innovative efforts to improve access and close the gaps in delivery of cryptogenic stroke care to ultimately reduce the secondary stroke burden. Clinical Perspective: Direct inpatient implantation of ICMs in cryptogenic stroke allows increased rates of early long-term cardiac rhythm monitoring and detection of AF. Collaborative clinical practice with inpatient ICM implantation by vascular and interventional neurologists is feasible and safe. This novel approach could potentially increase access to cardiac rhythm monitoring and exemplify patient-centered care.

  • Safety, Efficiency, and Efficacy of Protocolized Contrast-Enhanced Imaging in Acute Stroke Evaluation

    by Nathanael J. Lee, Fred Rincon, Robin Dharia

    Background and Purpose: Computed tomography angiography and perfusion studies have increasingly become a part of acute stroke evaluation. However, the volume, benefit, and scope of need for imaging is sometimes debated. Purpose: This study evaluated the safety, efficiency, and efficacy of changes to the acute stroke evaluation protocol at our academic institution. Previously, contrast-enhanced imaging was “opt-in” and ordered upon suspicion of large vessel occlusion. This was subsequently transitioned to one where contrast-enhanced imaging was automatically ordered for all patients with “opt-out” of imaging if felt appropriate. Methods: We performed a retrospective, case–control study that included patients evaluated for acute stroke management before and after the protocol change. Six hundred forty-seven patients met criteria for study involvement, of which 258 were in the preprotocol and 389 in the postprotocol group. Results: There was no significant difference in rate of acute kidney injury and no delay in door-to-needle time. There was significant improvement in door-to-groin puncture times (49.9 minutes) for typical cases and increase in monthly rate of endovascular therapy (EVT). Conclusion: Protocolization of contrast-enhanced imaging for acute stroke evaluation proved safe with respect to renal function, did not delay door-to-needle time, improved door-to-groin puncture time, and lead to higher rates of EVT.


  • Monocular visual loss as the presenting symptom of COVID-19 infection

    by Ann P. Murchison, Ahmad Sweid, Robin Dharia, Thana N. Theofanis, Stavropoula I. Tjoumakaris, Pascal M. Jabbour, Jurij R. Bilyk


  • Anti-coagulant and anti-platelet therapy in the COVID-19 patient: a best practices quality initiative across a large health system

    by Ryan A. Watson, Drew M. Johnson, Robin N. Dharia, Geno J. Merli, John U. Doherty

    The coronavirus disease 2019 (COVID-19) pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has challenged health care systems and physicians worldwide to attempt to provide the best care to their patients with an evolving understanding of this unique pathogen. This disease and its worldwide impact have sparked tremendous interest in the epidemiology, pathogenesis, and clinical consequences of COVID-19. This accumulating body of evidence has centered around case series and often empiric therapies as controlled trials are just getting underway. What is clear is that patients appear to be at higher risk for thrombotic disease states including acute coronary syndrome (ACS), venous thromboembolism (VTE) such as deep vein thrombosis (DVT) or pulmonary embolism (PE), or stroke. Patients with underlying cardiovascular disease are also at higher risk for morbidity and mortality if infected. These patients are commonly treated with anticoagulation and/or antiplatelet medications and less commonly thrombolysis during hospitalization, potentially with great benefit but management of these medications can be difficult in potentially critically ill patients. In this paper, we review the current guidelines, consensus statements, and emerging evidence for a wide range of cardiovascular disease states with special focus on anticoagulant and antiplatelet therapy. Our goal is to provide guidance for treatment of the cardiovascular patient with COVID-19 in the face of a rapidly evolving understanding of this virus and its complications. Preamble: Anticoagulant and antiplatelet therapies are a major cause of inpatient morbidity and mortality. This is amplified in critically ill patients. COVID-19 patients present special challenges due to rapidly changing clinical status. In an effort to align practice patterns across a large health system (Jefferson Health 2,622 staffed inpatient beds and 319 intensive care unit (ICU) beds across 14 facilities), a task force was assembled to address the utilization of anti-thrombotic and anti-platelet therapy in COVID-19 positive or suspected patients. The task force incorporated experts in Cardiology, Vascular Medicine, Hematology, Vascular Surgery, Pharmacy, and Vascular Neurology. Current guidelines, consensus documents, and policy documents from specialty organizations were used to formulate health system recommendations. Our deliberations and treatment recommendations are summarized here. Objective: To provide guidance to the utilization of antithrombotic and antiplatelet therapies in patients with known or suspected COVID-19.